Merck

Merck, BGI collaborate

Tuesday, September 13, 2011 01:05 PM

Merck and BGI have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies. Under the agreement scientists from Merck and BGI will work closely together to identify and characterize biomarkers with an emphasis on drug discovery, drug development and diagnostics applications across a wide range of therapeutic areas.

More... »

Merck, F-Star ink research agreement

Wednesday, September 7, 2011 02:43 PM

Merck Serono, Darmstadt, Germany, has reported that a research, license and commercialization agreement was signed with F-Star, Vienna, Austria, for the discovery of new antibody-derived therapeutics against inflammatory disease targets, using F-Star's Modular Antibody Technology.

More... »

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

PPD names chief scientific officer of BioDuro

Wednesday, August 17, 2011 11:43 AM

PPD has named Jasmine (Jisong) Cui, Ph.D., chief scientific officer of BioDuro, a PPD Company. Cui will provide scientific leadership to BioDuro's integrated drug discovery services across a range of disease areas and expand its use of novel technologies for small and large molecules and in stem cells and imaging.

More... »

DecisionView to launch enrollment-centric metrics

Monday, August 15, 2011 08:00 AM

Clinical trial enrollment-focused software maker DecisionView is launching what it says will be the first benchmarking effort to focus tightly on enrollment metrics.

More... »

Merck receives subpoena regarding marketing and selling of drugs

Monday, August 8, 2011 01:34 PM

Merck has received a subpoena from the US Department of Justice as part of a criminal investigation into the marketing of various drugs. The feds want info about marketing and selling these drugs - Temodar, which treats brain tumors; the PegIntron hepatitis C treatment; and Intron A, which treats certain cancers - from 2004 through the present, according to Pharmalot.

More... »

Merck to cut 12K jobs

Friday, July 29, 2011 12:55 PM

Merck plans to slash thousands more jobs by late 2015 to wring out additional annual cost savings of up to $1.5 billion that can be plowed back into research and deal making, according to Reuters.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

Pfizer to open research center in San Francisco’s Mission Bay

Friday, July 22, 2011 01:28 PM

Boosting Mission Bay's goal of becoming a hub for cutting-edge biotech, Pfizer has plans to establish a research center at the 303-acre former industrial site overlooking San Francisco Bay, according to the San Francisco Chronicle.

More... »

EMD Serono names Hoyes president

Wednesday, July 20, 2011 11:33 AM

EMD Serono, an affiliate of Germany-based Merck, has named James Hoyes president. He will be responsible for driving the strategic direction of the U.S. commercial organization as well as managing the day-to-day business of the U.S. affiliate of Merck. Hoyes will also serve as a member of the executive management board for Merck Serono, the global pharmaceuticals division of Merck.

More... »